Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in Sao Paulo state

Autor(es)

Moreira, Regina Celia ^[1] ; de Torres Santos, Ana Paula ^{[1, 2]} ; Lisboa-Neto, Gaspar ^[3] ; Jacintho Mendes-Correa, Maria Cassia ^[3] ; Lemos, Marcilio Figueiredo ^[1] ; Malta, Fernanda Mello ^[4] ; Ferraz Santana, RAbia Anita ^[5] ; Fernando Dastoli, Gregorio Tadeu ^[5] ; Duarte de Castro, Vanessa Fusco ^[5] ; Rebello Pinho, Joao Renato ^{[5, 4]}

Afiliação do(s) autor(es)

^[1] Adolfo Lutz Inst, Virol Ctr, Lab Viral Hepatitis, Ave Dr Arnaldo 355, BR-01246902 Sao Paulo, SP - Brazil

^[2] Univ Sao Paulo, Hosp Clin, Lab Imunol, Div Lab Cent, Fac Med, Sao Paulo, SP - Brazil

^[3] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, SP - Brazil

^[4] Univ Sao Paulo, Lab Trop Gastroenterol & Hepatol Joao de Queiroz, Inst Trop Med, Dept Gastroenterol, Sch Med, Sao Paulo, SP - Brazil

^[5] Hosp Israelita Albert Einstein, Albert Einstein Med Diagnost, Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: ARCHIVES OF VIROLOGY; v. 163, n. 10, p. 2757-2764, OCT 2018.
• Citações Web of Science: 1

Resumo

Hepatitis C (HCV)-infected patients are treated with direct-acting antiviral agents (DAAs) in highly effective, well-tolerated, all-oral regimens. However, naturally occurring resistance-associated amino acid substitutions (RASs) may be selected during treatment. This study aimed to screen naturally occurring RASs NS3/NS4A inhibitors (PIs). Samples were obtained from DAA naive patients, living in Sao Paulo state, Brazil. Screening for RASs in the HCV NS3 region was conducted in 859 samples from HCV-infected patients, of which 425 and 434 samples were subtype la and lb, respectively. HCV-RNA was extracted, amplified, and sequenced. The overall prevalence of RASs to HCV PIs was 9.4%. The following RASs were observed in HCV-1a subtype infected patients: V36L (2.6%), T54S (1.6%), V55I/A (1.2% / 8.9%, respectively), Q80K (2.1%), R155K (0.5%), and D168E (0.2%); and in HCV-1b infected patients: V36L (0.7%), T54A/S (0.2% and 0.5%, respectively), V55A (0.5%), Q80K (0.2%), D168E (1.6%), and M175L (0.5%). HCV la infected subjects had higher serum viral load than that seen in patients infected with HCV 1b. There was no difference between the proportions of NS3 RASs with regards to geographic distribution within the investigated areas. These findings should be supported by additional studies in Brazil to help in the formation of local clinical guidelines for managing hepatitis C. (AU)

• Processo FAPESP: 17/01809-9 - Caracterização de mutações de resistência primária para as drogas antivirais de ação direta (DAA) para o vírus da Hepatite C
• Beneficiário: Regina Célia Moreira
• Modalidade de apoio: Auxílio à Pesquisa - Regular